

Mette SÃ¸ndergaard Deleuran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7465220/publications.pdf>

Version: 2024-02-01

83
papers

6,694
citations

136950

32
h-index

66911

78
g-index

85
all docs

85
docs citations

85
times ranked

5159
citing authors

#	ARTICLE	IF	CITATIONS
1	Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2016, 375, 2335-2348.	27.0	1,467
2	Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 657-682.	2.4	727
3	Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 850-878.	2.4	519
4	ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 729-747.	2.4	329
5	Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1176-1193.	2.4	316
6	Increasing Comorbidities Suggest that Atopic Dermatitis is a Systemic Disorder. <i>Journal of Investigative Dermatology</i> , 2017, 137, 18-25.	0.7	283
7	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2717-2744.	2.4	220
8	Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 1114-1121.	5.7	201
9	When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 623-633.	1.2	170
10	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 377-388.	1.2	155
11	Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 443-456.	6.7	130
12	<scp>TSLP</scp>, <scp> IL</scp>-31, <scp>IL</scp>-33 and <scp>sST</scp>-2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1930-1938.	2.4	125
13	Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). <i>Journal of Dermatological Science</i> , 2019, 94, 266-275.	1.9	121
14	Emerging Terbinafine Resistance in <i>Trichophyton</i> : Clinical Characteristics, Squalene Epoxidase Gene Mutations, and a Reliable EUCAST Method for Detection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	109
15	The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. <i>British Journal of Dermatology</i> , 2020, 182, 1331-1342.	1.5	102
16	European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e241-e242.	2.4	99
17	The European treatment of severe atopic eczema in children taskforce (TREAT) survey. <i>British Journal of Dermatology</i> , 2013, 169, 901-909.	1.5	94
18	Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis. <i>American Journal of Medicine</i> , 2015, 128, 1325-1334.e2.	1.5	94

#	ARTICLE	IF	CITATIONS
19	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1644-1659.	2.4	85
20	Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 567-577.	6.7	78
21	Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. <i>Pediatric Allergy and Immunology</i> , 2015, 26, 306-315.	2.6	71
22	Contact allergy in children with atopic dermatitis: a systematic review. <i>British Journal of Dermatology</i> , 2017, 177, 395-405.	1.5	57
23	Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. <i>British Journal of Dermatology</i> , 2017, 176, 1486-1491.	1.5	56
24	Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the <sc>TOPICOP</sc> score. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1713-1719.	5.7	52
25	Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1224-1231.	2.4	50
26	Global Allergy Forum and 3rd Davos Declaration 2015. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 588-592.	5.7	47
27	Purified Der p1 and p2 Patch Tests in Patients with Atopic Dermatitis: Evidence for Both Allergenicity and Proteolytic Irritancy: Investigative Reports. <i>Acta Dermato-Venereologica</i> , 1998, 78, 241-243.	1.3	46
28	Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00402.	1.3	45
29	Clinical heterogeneity and differential diagnosis of atopic dermatitis. <i>British Journal of Dermatology</i> , 2014, 170, 2-6.	1.5	44
30	Nomenclature and clinical phenotypes of atopic dermatitis. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110029.	2.5	43
31	Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 351-358.	1.2	39
32	Contact allergy in Danish children: Current trends. <i>Contact Dermatitis</i> , 2018, 79, 295-302.	1.4	38
33	Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 393-408.	6.7	36
34	Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 304-313.	2.5	33
35	Description and characterization of a penicillin-resistant <i>Streptococcus dysgalactiae</i> subsp <i>equisimilis</i> clone isolated from blood in three epidemiologically linked patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3376-3380.	3.0	30
36	<sc>TRE</sc> atment of <sc>AT</sc> opic eczema (<sc>TREAT</sc>) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. <i>British Journal of Dermatology</i> , 2019, 181, 492-504.	1.5	29

#	ARTICLE	IF	CITATIONS
37	Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. <i>British Journal of Dermatology</i> , 2019, 181, 196-197.	1.5	28
38	Children with atopic dermatitis may have unacknowledged contact allergies contributing to their skin symptoms. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 428-436.	2.4	27
39	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e308-e311.	2.4	27
40	Treatment of Atopic Eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries. <i>British Journal of Dermatology</i> , 2019, 180, 790-801.	1.5	26
41	Current pharmaceutical developments in atopic dermatitis. <i>Current Opinion in Pharmacology</i> , 2019, 46, 7-13.	3.5	26
42	The International Treatment of Atopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2014-2016.	0.7	25
43	The European Treatment of Atopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema*. <i>British Journal of Dermatology</i> , 2020, 183, 1073-1082.	1.5	25
44	Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e362-e365.	2.4	24
45	European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e839-e842.	2.4	22
46	Treatment of Atopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. <i>Trials</i> , 2017, 18, 87.	1.6	21
47	Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. <i>Dermatology and Therapy</i> , 2021, 11, 1357-1372.	3.0	19
48	Cyclosporine and Extracorporeal Photopheresis are Equipotent in Treating Severe Atopic Dermatitis: A Randomized Cross-Over Study Comparing Two Efficient Treatment Modalities. <i>Frontiers in Medicine</i> , 2014, 1, 33.	2.6	18
49	Characterization and scoring of skin changes in severe acute malnutrition in children between 6 months and 5 years of age. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2463-2469.	2.4	18
50	Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials. <i>Journal of Dermatological Treatment</i> , 2022, 33, 266-277.	2.2	17
51	Short Communications. <i>Contact Dermatitis</i> , 2000, 43, 169-185.	1.4	15
52	Treatment of Atopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema. <i>British Journal of Dermatology</i> , 2020, 182, 1423-1429.	1.5	14
53	An Emollient Containing Aquaphilus dolomiae Extract is Effective in the Management of Xerosis and Pruritus: An International, Real-World Study. <i>Dermatology and Therapy</i> , 2020, 10, 1013-1029.	3.0	14
54	Healthcare utilization in Danish children with atopic dermatitis and parental topical corticosteroid phobia. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 331-341.	2.6	14

#	ARTICLE	IF	CITATIONS
55	Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1608-1616.	2.2	14
56	A Case Series Study of Eighty-Five Chronic Spontaneous Urticaria Patients Referred to a Tertiary Care Center. <i>Annals of Dermatology</i> , 2014, 26, 73.	0.9	13
57	Attention-Deficit/Hyperactivity Disorder in Atopic Dermatitis: An Appraisal of the Current Literature. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2016, 29, 181-188.	0.8	13
58	Measuring serum concentrations of interleukin-33 in atopic dermatitis is associated with potential false positive results. <i>SpringerPlus</i> , 2016, 5, 33.	1.2	11
59	Disease severity and trigger factors in Danish children with atopic dermatitis: a nationwide study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 948-957.	2.4	11
60	Concerns related to the coronavirus disease 2019 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e773-e776.	2.4	10
61	Orofacial granulomatosis in children can be the initial manifestation of systemic disease: a presentation of two cases. <i>Dermatology Reports</i> , 2014, 6, 5039.	0.8	8
62	Photosensitivity in atopic dermatitis complicated by contact allergy to common sunscreen ingredients. <i>Contact Dermatitis</i> , 2016, 74, 56-58.	1.4	8
63	Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00504.	1.3	8
64	Therapeutic education in atopic dermatitis: A position paper from the International Eczema Council. <i>JAAD International</i> , 2021, 3, 8-13.	2.2	8
65	Drug survival of systemic immunosuppressive treatments for atopic dermatitis in a long-term pediatric cohort. <i>International Journal of Women's Dermatology</i> , 2021, 7, 708-715.	2.0	8
66	Appraisal of Proactive Topical Therapy in Atopic Dermatitis: Pros and Cons. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 775-783.	6.7	8
67	Methylprednisolone Therapy in Acute Hemorrhagic Edema of Infancy. <i>Case Reports in Dermatological Medicine</i> , 2014, 2014, 1-3.	0.3	7
68	Memory Buttons in Combination with Mobile Application-Induced Objective and Subjective Effects in Patients with Atopic Dermatitis. <i>Dermatology Research and Practice</i> , 2020, 2020, 1-6.	0.8	7
69	Systemic Treatment of Severe Atopic Dermatitis in Children and Adults. <i>Current Treatment Options in Allergy</i> , 2014, 1, 384-396.	2.2	6
70	Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A Systematic Review of Best-Evidenced Treatment Options. <i>Dermatology</i> , 2022, 238, 950-960.	2.1	6
71	Allergic Contact Dermatitis Caused by Tert-Butylphenol-Formaldehyde Resin in Orthopedic Braces. <i>Pediatric Dermatology</i> , 2016, 33, e204-e205.	0.9	5
72	Position statement on the role of nurses in therapeutic patient education in atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2143-2148.	2.4	5

#	ARTICLE	IF	CITATIONS
73	Severe Infantile Bullous Pemphigoid Treated with Dapsone after Bridging with Systemic Glucocorticoid. <i>Case Reports in Dermatology</i> , 2019, 11, 187-193.	0.8	4
74	How "benign" is cutaneous mastocytosis? A Danish registry-based matched cohort study. <i>International Journal of Women's Dermatology</i> , 2020, 6, 294-300.	2.0	4
75	Topical Calcineurin Inhibitors, Topical Glucocorticoids and Cancer in Children: A Nationwide Study. <i>Acta Dermato-Venereologica</i> , 2014, 96, 834-5.	1.3	3
76	Combined dapsone and sulfapyridine for the treatment of therapy-resistant linear IgA bullous dermatosis: Two case reports. <i>JAAD Case Reports</i> , 2022, 21, 119-122.	0.8	3
77	Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome Manifesting as Lymphocytic Interstitial Pneumonia and Treatment-Resistant Bullous Pemphigoid. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2021, 34, 76-79.	0.8	2
78	Effective clinical study recruitment of patients with atopic dermatitis through social media. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e922-e923.	2.4	2
79	Editorial overview: Dermatology is moving forward. <i>Current Opinion in Pharmacology</i> , 2019, 46, vi-viii.	3.5	0
80	SAT0006...T-CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3 (TIM-3) IS INCREASED IN ACTIVE RHEUMATOID ARTHRITIS AND ASSOCIATED WITH CLINICAL DISEASE ACTIVITY AND RADIOGRAPHIC PROGRESSION. , 2019, , .		0
81	Methotrexate in atopic eczema " Reply to a letter. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e155-e156.	2.4	0
82	Real-world evidence vs. randomized control trials. <i>British Journal of Dermatology</i> , 2020, 182, 275-276.	1.5	0
83	Atopic dermatitis and psoriasis: so much more than "just skin diseases" <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 5.	1.0	0